Form 4: Centessa CBO Weinhoff Boosts Equity Holdings

Centessa Pharmaceuticals' Chief Business Officer, Gregory M. Weinhoff, increased his beneficial ownership through new RSU and option grants, alongside a tax-related share disposition.

Summary

• Gregory M. Weinhoff, Chief Business Officer of Centessa Pharmaceuticals plc (CNTA), reported changes in his beneficial ownership.
• On February 1, 2026, 14,158 Ordinary Shares were disposed of at a price of $24.57 per share to cover tax withholding obligations related to the vesting of restricted share units.
• Following this disposition, Mr. Weinhoff directly owned 108,121 Ordinary Shares.
• On February 2, 2026, Mr. Weinhoff acquired 31,000 Restricted Share Units (RSUs) under the Centessa Pharmaceuticals plc Amended and Restated 2021 Stock Option and Incentive Plan.
• These RSUs represent the contingent right to receive one Ordinary Share each and will vest in four equal annual installments, with the first vesting on February 2, 2027.
• After the RSU acquisition, Mr. Weinhoff directly owned 139,121 Ordinary Shares.
• Also on February 2, 2026, Mr. Weinhoff acquired options to purchase 123,000 Ordinary Shares at an exercise price of $25.19 per share.
• These share options will vest in 1/48th equal monthly installments, with the first installment vesting on March 2, 2026, and expire on February 2, 2036.
• A substitute Power of Attorney was filed, appointing Raphael Deferiere as attorney-in-fact for Gregory M. Weinhoff for SEC filings, effective August 11, 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively as it reflects routine executive compensation through significant equity grants, aligning management's interests with long-term company performance, while the share disposition is a standard tax-related event.

Positives

• The grant of 31,000 Restricted Share Units (RSUs) and options to purchase 123,000 Ordinary Shares aligns management's incentives with long-term shareholder value.
• The multi-year vesting schedules for both RSUs and options promote executive retention and sustained performance.

Negatives

• The disposition of 14,158 Ordinary Shares at $24.57 was solely to cover tax withholding obligations, which is a routine event and not indicative of a negative outlook.

Future Outlook

The future outlook includes the vesting of 31,000 Restricted Share Units in four equal annual installments starting February 2, 2027, and the vesting of 123,000 Share Options in 1/48th equal monthly installments starting March 2, 2026, with an expiration date of February 2, 2036.

Industry Context

StockSavvy.ai notes that executive compensation packages often include a mix of equity awards like Restricted Share Units (RSUs) and stock options. These instruments are designed to align management incentives with long-term shareholder value and are a common practice in the biotechnology and pharmaceutical sectors to attract and retain key talent.

Comparison to Industry Standards

• StockSavvy.ai observes that equity compensation structures, including multi-year vesting schedules for RSUs and options, are standard practice across the biotechnology and pharmaceutical sectors, similar to compensation plans seen at comparable companies like Moderna or BioNTech, to ensure executive retention and performance alignment.
• The disposition of shares to cover tax withholding is a routine and expected event when equity awards vest, consistent with practices observed across publicly traded companies in various industries.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grants align the Chief Business Officer's financial interests with the company's long-term performance, potentially benefiting shareholders through motivated leadership.
• Employees: The compensation structure reflects standard practices for executive incentives, which can influence overall compensation philosophy within the company.

Next Steps

• Continued vesting of 31,000 Restricted Share Units annually, with the first installment on February 2, 2027.
• Continued monthly vesting of 123,000 Share Options, with the first installment on March 2, 2026.

Key Dates

Recommendation

The filing details routine executive compensation through equity grants and a tax-related share disposition, which are standard and do not provide new fundamental information to alter an investment thesis. These transactions are expected and do not suggest a significant change in the company's outlook or valuation.

Keywords

Centessa Pharmaceuticals, CNTA, Insider Transaction, Form 4, Executive Compensation, Restricted Share Units, Stock Options, Beneficial Ownership, Equity Grant